CN102475708A - Separate type water suspension medicine comprising fluticasone propionate and adjuvant-containing water and used for treating skin diseases - Google Patents
Separate type water suspension medicine comprising fluticasone propionate and adjuvant-containing water and used for treating skin diseases Download PDFInfo
- Publication number
- CN102475708A CN102475708A CN2010105567782A CN201010556778A CN102475708A CN 102475708 A CN102475708 A CN 102475708A CN 2010105567782 A CN2010105567782 A CN 2010105567782A CN 201010556778 A CN201010556778 A CN 201010556778A CN 102475708 A CN102475708 A CN 102475708A
- Authority
- CN
- China
- Prior art keywords
- adjuvant
- water
- fluticasone propionate
- compositions described
- acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicinal Preparation (AREA)
Abstract
The invention relates to a separate type water suspension medicine comprising fluticasone propionate and adjuvant-containing water and used for treating skin diseases, which comprises separately packed fluticasone propionate of D90 particle size 0.1-10 mum and separately packed water containing one or more adjuvants for dermatologic medicine. The separately packed insoluble dermatologic medicine has a preferably D90 particle size of 1-10 mum, and a particle shape of a sphere or a spheroid.
Description
Technical field:
The present invention relates to a kind of dermatologic thing, by forming jointly as the water that contains one or more skin pharmaceutic adjuvants of the water-fast fluticasone propionate of packing separately, independent packing.
Background technology:
Scytitis such as eczema (eczema), allergic dermatitis (allergic dermatitis), atopic dermatitis (atopic dermatitis) urticaria (Urticaria) etc. all are to be caused allergy and caused scytitis by certain allergen.
In the percutaneous drug delivery system; Skin is that medicine gets into intravital main barrier, discovers and has only the only a few medicine to have good skin permeability, and most medicines are difficult for passing human body skin, and this is effective; Barrier optionally, fat-soluble comparatively speaking higher medicine passes epidermis more easily.The treatment dermatosis; Modal preparation type is the Transdermal absorption administration, transdermal drug delivery system or transdermal formulation (transdermal thrapeutic systems, transdermal drug delivery systems; Be called for short TTS; TDDS): be meant in the skin surface administration, make medicine pass through skin, get into the novel form that the body circulation produces whole body or local therapeutic effects with constant rate of speed (or near constant rate of speed).Its advantage applies exists: drug absorption does not receive factor affecting such as pH in the digestive tract, food, transhipment time; Avoid liver first-pass effect; Overcome because of absorbing the too high untoward reaction that causes of too fast generation blood drug level; The sustainable Control injection speed, flexible administration etc., common transdermal drug delivery system comprises cataplasma, ointment, liniment, gel etc.
But because above-mentioned preparation need add a large amount of adjuvants; These adjuvants can produce various untoward reaction to skin simultaneously, and for example some patient can produce allergic symptom to adjuvant, and especially the adult is thinner for the infant skin below 2 years old; There is stimulation in adjuvants such as the long-chain fat in unguentum, the gel, ethanol to skin; So be prone to irritated crowd and the infant below 2 years old to part, should reduce the use of excipient substance as far as possible, water suspension just has similar effects.But preparation as treatment skin; A little less than the drug action of water suspension; Key is that water suspension does not have fat-soluble adjuvant such as lanoline etc., so the percutaneous ability of this kind preparation is relatively poor, so in fact this kind water suspension dosage form is not treating dermatosis through Transdermal absorption.
Simultaneously, also there is a kind of difficulty of preparation in water suspension through Transdermal absorption, if the suspendible particle is bigger; Then can't pass through epidermal tissue,, but compare with macroparticle if the suspendible particle is too small like nanoscale; The small-particle specific surface area is big; Have higher surface energy, so this system is adsorbed onto the macroparticle surface for reduce the molecule disengaging small-particle that its surface energy makes the small-particle surface as far as possible through solution diffusion.Finally, small-particle diminishes gradually and macroparticle is grown up gradually, i.e. the Ostwald ripening phenomenon.The speed of Ostwald ripening is mainly by molecular diffusion and surface action decision.Suspended particles is because its particle size distribution is inhomogeneous; So especially obvious ((Welin-Berger K of Ostwald ripening phenomenon; Bergenstahl B.Inhibition of Ostwald ripening in local anesthetic emulsions by using hydrophobic excipients in the disperse phase [J] .Int J Pharm; 2000,200 (2): 249-260.).
The microgranule suspensoid belongs to the thermokinetics Unstable Systems, and particle has accumulative trend, to minimize its surface free energy.Because the specific surface area of microgranule is big, so particle is in contact with one another the chance increase of collision, the stronger power that attracts each other of existence between the while particle; Intermolecular force is strong; Particle is easy to take place irreversible aggrengation to reduce its surface energy (Wong J, Brugger A, Khare A; Et al.Suspensions for intravenous (IV) injection:a review of development; Preclinical and clinical aspects [J] .Adv Drug Deliv Rev, 2008,60 (8): 939-954; Kesisoglou F, Panmai S, Wu Y.Nanosizing--oral formulation development and biopharmaceutical evaluation [J] .Adv Drug Deliv Rev, 2007,59 (7): 631-644.).
How to solve particle problem of unstable in the microgranule suspensoid; Be to need one of problem that solves in the galenic pharmacy always; But no matter through adding adjuvant, still improve particle structure, all can't guarantee microgranule suspensoid long preservation; Especially skin class suspensoid belongs to repeatedly use, the problems referred to above more likely occur.
Summary of the invention:
Through test; The discovery that we are surprised; To be made up of jointly the water that contains one or more skin pharmaceutic adjuvants that is 0.1-10 μ m dermatologic thing as the particle diameter of packing separately that is insoluble in water, packs separately, both can form the conditioned water for skin suspensoid through simple concussion in use.This brand-new Transdermal absorption is treated the dosage form of dermatosis; Both can guarantee in use that water suspension can see through the skin treating dermatosis with particulate form; Can store the long period again, avoid occurring the Ostwald ripening phenomenon and cause granule to become big, thereby influence the curative effect of medicine.
The key of technology is that the D90 particle diameter that is insoluble in water of packing is the storage of 0.1-10 μ m dermatologic thing through certain hour separately; Degradation problem under caking, particle aggregation, the dispersibility do not occur, still can pass through simple concussion and form even suspension and be prone to by skin absorbs with the independent water that contains one or more skin pharmaceutic adjuvants of packing.
The particle diameter of indication of the present invention is the D90 particle diameter, and promptly the cumulative particle sizes distribution number of a sample reaches 90% o'clock pairing particle diameter.Its physical significance be particle diameter less than it granule account for 90%.
The present invention provides a kind of Transdermal absorption to treat dermopathic pharmaceutical composition, is made up of jointly the water that contains one or more skin pharmaceutic adjuvants that is 0.1-10 μ m fluticasone propionate as the D90 particle diameter of packing separately that is insoluble in water, packs separately.The D90 particle diameter that is insoluble in water dermatologic thing of described independent packing is preferably 1-10 μ m, and particulate form is spherical or type sphere.Described pharmaceutical composition can also increase the utensil of a kind of hybrid medicine and water.
The consumption of said fluticasone propionate is 0.01%～0.2%.Preferred 0.05%～0.1%.
Adjuvant in the water that contains one or more skin pharmaceutic adjuvants of said independent packing comprises one or more in pH regulator agent, osmotic pressure regulator, viscosity modifier, penetrating agent, surfactant or the stabilizing agent.PH regulator agent in the said adjuvant is one or more in phosphoric acid and salt, boric acid and salt thereof, citric acid and salt thereof, acetic acid and salt thereof, tartaric acid and salt thereof, hydrochloric acid, sodium hydroxide, potassium hydroxide, sodium carbonate, potassium carbonate, sodium bicarbonate, potassium bicarbonate, the tromethane.In preferred acetic acid, hydrochloric acid, sodium hydroxide, potassium hydroxide, sodium carbonate, potassium carbonate, sodium bicarbonate, the potassium bicarbonate one or more.
Osmotic pressure regulator in the said adjuvant is one or more in glycerol, propylene glycol, sodium chloride, potassium chloride, Sorbitol, the mannitol.The preferred sodium chloride that adopts 0.4%-0.9%.
Viscosity modifier in the said adjuvant is one or more in sodium carboxymethyl cellulose, hydroxyethyl-cellulose, hydroxypropyl emthylcellulose, hydroxypropyl cellulose, polyvinyl alcohol, carboxy vinyl polymer, the polyvinyl pyrrolidone, and consumption is 0.1%～2%.
The optional non-ionic surface active agent of surfactant in the said adjuvant.Be tween 80, polyoxyethylene hydrogenated Oleum Ricini 60, Polyethylene Glycol-stearate; Macrogol 4000, lecithin, sucrose ester; Polyoxyethylene alkyl ether, one or more in polyoxyethylene polyoxypropylene glycol and analog thereof, poloxamer, the tyloxapol, consumption is preferably 0.1%～2%.
Stabilizing agent in the said adjuvant is a disodiumedetate.Preferred stabilizing agent is 0.1%～0.01% disodiumedetate.
Penetrating agent in the said adjuvant is one or more in azone, sulfoxide and analog thereof, ethanol, aliphatic alcohol, pyrrolones, fatty acid, menthol, quintessence oil, the Borneolum Syntheticum, is selected from azone, laurocapram, thionyl chloride, decyl methyl sulfoxide, propylene glycol, N-methyl-2-pyrrolidone, 2-pyrrolidone, lauric acid, oleic acid, linoleic acid, linolenic acid, menthol, ledum terpenes, the eucalyptus oil one or more.
Said dermal drug compositions is characterized in that the pH of the water that contains one or more skin pharmaceutic adjuvants of described independent packing is selected from 5-7.
Described pharmaceutical composition is characterized in that the method for micronization of fluticasone propionate can adopt spray drying method, fluid bed supersonic airstream comminuting method, high speed polishing, ball-milling method, fluid energy mill method, solvent method, the preparation of CO2 supercritical methanol technology.Said method of micronization adopts spray drying method, the preparation of CO2 supercritical auxiliary atomizing method.
Described pharmaceutical composition is characterized in that said dermatologic thing can adopt the packaged of single or multiple dosage, and the packaged of said single or multiple dosage is the water-tight packing.The packaged of said multidose is the aluminium foil bubble-cap.
Described pharmaceutical composition, the application in preparation treatment human or animal scytitis medicine.
Described pharmaceutical composition, the application in preparation treatment human or animal skin eczema, daylight rash medicine.
Described pharmaceutical composition, the application in the preparation treatment is below 2 years old in the infant scytitis medicine.
Described pharmaceutical composition, diaper rash, seborrheic dermatitis, the atoipc dermatitis of infant are used in the preparation treatment is below 2 years old.
Pharmaceutical composition provided by the invention is made up of the drug microparticles of independent packing and the water that contains excipient substance, and both can form the conditioned water for skin suspensoid through simple concussion in use and can keep the stability of certain hour.Simultaneously because medicine separates packing with water, when the disease degree not simultaneously, can adjust and join the water Chinese medicine dosage that contains excipient substance; Make single medicine can have multiple dosage in actual use; Be convenient to the patient and use, medicine provided by the invention simultaneously, thereby with also can keep the particle diameter of medicine to guarantee that suspendible is stable within a certain period of time after the suspendible water mixes; Therefore also reduce the waste of medicine, met the requirement of low carbon emission reduction.
The specific embodiment
The particle diameter of following embodiment indication is the D90 particle diameter.
One, the preparation of Transdermal absorption medicine microgranule
The capsule of embodiment 1 to 10 resulting drug microparticles packing is a plant capsule, and capsule is used the aluminium foil blister package after the packing.
Embodiment 1
The 0.2g fluticasone propionate is dissolved in ethanol, after the filtration, the filtrating spray drying, micronization makes particle diameter reach 3 μ m, sterilizes after crossing 3 mixings of 200 mesh sieves, is divided in No. 3 capsules, and every capsules has fluticasone propionate 2mg.Electron microscopic observation microgranule type of being is spherical.
Process conditions are: inlet temperature is 105 ℃, and outlet temperature is 68 ℃, throughput 90%, and the jet expansion internal diameter is 0.1cm, nozzle air flow velocity 800ml/min, sample introduction speed 50mL/h
Embodiment 2
1g is dissolved in ethanol with fluticasone propionate, after the filtration, and the filtrating spray drying, micronization makes it particle diameter and reaches 3 μ m, and with sterilizing behind 3 mixings of 200 mesh sieves, branch installs in No. 3 capsules, and every capsules has fluticasone propionate 1mg.Electron microscopic observation microgranule type of being is spherical.
Process conditions are: inlet temperature is 105 ℃, and outlet temperature is 70 ℃, throughput 90%, and the jet expansion internal diameter is 0.1cm, nozzle air flow velocity 800ml/min, sample introduction speed 50mL/h.
Embodiment 3
0.5g is dissolved in ethanol with fluticasone propionate, and after the filtration, the filtrating spray drying makes it particle diameter and reaches 3 μ m, sterilizes after crossing 3 mixings of 200 mesh sieves, divides to install in No. 3 capsules, and every capsules has fluticasone propionate 0.5mg.Electron microscopic observation microgranule type of being is spherical.
Process conditions are: inlet temperature is 105 ℃, and outlet temperature is 68 ℃, throughput 90%, and the jet expansion internal diameter is 0.1cm, nozzle air flow velocity 800ml/min, sample introduction speed 50mL/h.
Embodiment 4
1g is dissolved in ethanol with fluticasone propionate, and after the filtration, the filtrating spray drying makes it particle diameter and reaches 2.5 μ m, sterilizes after crossing 3 mixings of 200 mesh sieves, divides to install in No. 3 capsules, and every capsules has fluticasone propionate 1mg.Electron microscopic observation microgranule type of being is spherical.
Process conditions are: inlet temperature is 105 ℃, and outlet temperature is 68 ℃, throughput 90%, and the jet expansion internal diameter is 0.1cm, nozzle air flow velocity 800ml/min, sample introduction speed 50mL/h.
Embodiment 5
1g is dissolved in ethanol with fluticasone propionate, and after the filtration, the filtrating spray drying makes it particle diameter and reaches 3 μ m, sterilizes after crossing 3 mixings of 200 mesh sieves, divides to install in No. 3 capsules, and every capsules has fluticasone propionate 1mg.Electron microscopic observation microgranule type of being is spherical.
Process conditions are: inlet temperature is 105 ℃, and outlet temperature is 68 ℃, throughput 90%, and the jet expansion internal diameter is 0.1cm, nozzle air flow velocity 800ml/min, sample introduction speed 50mL/h.
Embodiment 6
1g is dissolved in ethanol with fluticasone propionate, and after the filtration, the filtrating spray drying makes it particle diameter and reaches 3 μ m, sterilizes after crossing 3 mixings of 200 mesh sieves, divides to install in No. 3 capsules, and every capsules has fluticasone propionate 1mg.Electron microscopic observation microgranule type of being is spherical.
Process conditions are: inlet temperature is 105 ℃, and outlet temperature is 68 ℃, throughput 90%, and the jet expansion internal diameter is 0.1cm, nozzle air flow velocity 800ml/min, sample introduction speed 50mL/h.
Embodiment 7
0.5g is dissolved in ethanol with fluticasone propionate, and after the filtration, the filtrating spray drying makes it particle diameter and reaches 3 μ m, sterilizes after crossing 3 mixings of 200 mesh sieves, divides to install in No. 3 capsules, and every capsules has fluticasone propionate 0.5mg.Electron microscopic observation microgranule type of being is spherical.
Process conditions are: inlet temperature is 105 ℃, and outlet temperature is 68 ℃, throughput 90%, and the jet expansion internal diameter is 0.1cm, nozzle air flow velocity 800ml/min, sample introduction speed 50mL/h.
Embodiment 8
1g is dissolved in ethanol with fluticasone propionate, and after the filtration, the filtrating spray drying makes particle diameter reach 3 μ m, sterilizes after crossing 3 mixings of 200 mesh sieves, divides to install in No. 3 capsules, and every capsules has fluticasone propionate 1mg.Electron microscopic observation microgranule type of being is spherical.
Process conditions are: inlet temperature is 105 ℃, and outlet temperature is 68 ℃, throughput 90%, and the jet expansion internal diameter is 0.1cm, nozzle air flow velocity 800ml/min, sample introduction speed 50mL/h.
Embodiment 9
Utilize fluid energy mill (use the QM-3A of Nanjing Univ. Instrument Factory) to pulverize micronization the 0.2g fluticasone propionate and make it particle diameter and reach 3 μ m, sterilize after crossing 3 mixings of 200 mesh sieves, be divided in No. 3 capsules, every capsules has fluticasone propionate 2mg.The electron microscopic observation microgranule is not for there being the shape of confirming.
Embodiment 10
Utilize fluid energy mill (use the QM-3A of Nanjing Univ. Instrument Factory) to pulverize micronization the 1g fluticasone propionate and make it particle diameter and reach 3 μ m, sterilize after crossing 3 mixings of 200 mesh sieves, be divided in No. 3 capsules, every capsules has fluticasone propionate 1mg.The electron microscopic observation microgranule is not for there being the shape of confirming.
Embodiment 11
EDTA-2Na (disodiumedetate) 0.2g, sodium chloride is an amount of, sodium carboxymethyl cellulose 2.5g, poloxamer 0.5g, sodium hydroxide is an amount of, and adding distil water is to 1000g
Compound method: EDTA-2Na, sodium carboxymethyl cellulose, the poloxamer of recipe quantity are dissolved in the 500ml water for injection; Stir and dissolve clearly; Transfer pH to 5.5 with sodium hydroxide, transfer to wait with sodium chloride and ooze the water for injection that the back adds surplus, the airtight preservation of packing 1ml/ ampoule after the sterilization.
Embodiment 12
EDTA-2Na 0.1g, sodium chloride is an amount of, hydroxypropyl emthylcellulose 4g, N-methyl-2-pyrrolidone 5g, sodium hydroxide is an amount of, and adding distil water is to 1000g
Compound method: EDTA-2Na, hydroxypropyl emthylcellulose, the N-methyl-2-pyrrolidone of recipe quantity are dissolved in the 500ml water for injection; Stir and dissolve clearly; Transfer pH to 5.5 with sodium hydroxide, transfer to wait with sodium chloride and ooze the water for injection that the back adds surplus, the airtight preservation of packing 1ml/ ampoule after the sterilization.
Control Example 1-1
The water that microgranule that embodiment 1 is obtained and embodiment 11 obtain mixes according to the ratio of 2mg/ml, and sterilization is with ultrasonic wave concussion airtight preservation of packing 1ml/ ampoule after 30 seconds.
Control Example 1-2
The water that microgranule that embodiment 1 is obtained and embodiment 12 obtain mixes according to the ratio of 2mg/ml, and sterilization is with ultrasonic wave concussion airtight preservation of packing 1ml/ ampoule after 30 seconds.
Control Example 2-1
The water that microgranule that embodiment 2 is obtained and embodiment 11 obtain mixes according to the ratio of 1mg/ml, and sterilization is with ultrasonic wave concussion airtight preservation of packing 1ml/ ampoule after 30 seconds.
Control Example 2-2
The water that microgranule that embodiment 2 is obtained and embodiment 12 obtain mixes according to the ratio of 1mg/ml, and sterilization is with ultrasonic wave concussion airtight preservation of packing 1ml/ ampoule after 30 seconds.
Control Example 3-1
The water that microgranule that embodiment 3 is obtained and embodiment 11 obtain mixes according to the ratio of 0.5mg/ml, and sterilization is with ultrasonic wave concussion airtight preservation of packing 1ml/ ampoule after 30 seconds.
Control Example 3-2
The water that microgranule that embodiment 3 is obtained and embodiment 12 obtain mixes according to the ratio of 0.5mg/ml, and sterilization is with ultrasonic wave concussion airtight preservation of packing 1ml/ ampoule after 30 seconds.
Control Example 4-1
The water that microgranule that embodiment 4 is obtained and embodiment 11 obtain mixes according to the ratio of 0.5mg/ml, and sterilization is with ultrasonic wave concussion airtight preservation of packing 1ml/ ampoule after 30 seconds.
Control Example 4-2
The water that microgranule that embodiment 4 is obtained and embodiment 12 obtain mixes according to the ratio of 0.5mg/ml, and sterilization is with ultrasonic wave concussion airtight preservation of packing 1ml/ ampoule after 30 seconds.
Control Example 5-1
The water that microgranule that embodiment 5 is obtained and embodiment 11 obtain mixes according to the ratio of 1mg/ml, and sterilization is with ultrasonic wave concussion airtight preservation of packing 1ml/ ampoule after 30 seconds.
Control Example 5-2
The water that microgranule that embodiment 5 is obtained and embodiment 12 obtain mixes according to the ratio of 1mg/ml, and sterilization is with ultrasonic wave concussion airtight preservation of packing 1ml/ ampoule after 30 seconds.
Control Example 6-1
The water that microgranule that embodiment 6 is obtained and embodiment 11 obtain mixes according to the ratio of 1mg/ml, and sterilization is with ultrasonic wave concussion airtight preservation of packing 1ml/ ampoule after 30 seconds.
Control Example 6-2
The water that microgranule that embodiment 6 is obtained and embodiment 12 obtain mixes according to the ratio of 1mg/ml, and sterilization is with ultrasonic wave concussion airtight preservation of packing 1ml/ ampoule after 30 seconds.
Control Example 7-1
The water that microgranule that embodiment 7 is obtained and embodiment 11 obtain mixes according to the ratio of 0.5mg/ml, and sterilization is with ultrasonic wave concussion airtight preservation of packing 1ml/ ampoule after 30 seconds.
Control Example 7-2
The water that microgranule that embodiment 7 is obtained and embodiment 12 obtain mixes according to the ratio of 0.5mg/ml, and sterilization is with ultrasonic wave concussion airtight preservation of packing 1ml/ ampoule after 30 seconds.
Control Example 8-1
The water that microgranule that embodiment 8 is obtained and embodiment 11 obtain mixes according to the ratio of 1mg/ml, and sterilization is with ultrasonic wave concussion airtight preservation of packing 1ml/ ampoule after 30 seconds.
Control Example 8-2
The water that microgranule that embodiment 8 is obtained and embodiment 12 obtain mixes according to the ratio of 1mg/ml, and sterilization is with ultrasonic wave concussion airtight preservation of packing 1ml/ ampoule after 30 seconds.
Two, relevant pharmacodynamics test
Stability experiment
With embodiment 1-12, control Example 1-1 to 8-2 be divided into embodiment 1-10 group, control Example 1-1 to 8-2 organizes; Embodiment 11-12 organizes 500 every group; All the other every group 40 units; At 40 ℃ ± 2 ℃, carry out stability test under the situation of relative humidity 75% ± 5%, respectively at the D90 particle diameter of storage sampling survey medicine in the time of 0 month, 1 month, 3 months; Get 10 units at every turn; Wherein each 10 capsules getting of embodiment 1-10 group are before carrying out the particle diameter test, get 5 capsular medicines and in ampoule, mix, get 5 capsular medicines with water that 5 units that embodiment 11 obtains contain adjuvant respectively and mix in ampoule with the water that 5 units that embodiment 12 obtains contain adjuvant respectively, and measure particle diameter immediately after 10 seconds with descending to shake on hand; Control Example 1-1 to 8-2 group is before carrying out the particle diameter test, with descending concussion to measure particle diameter immediately after 10 seconds on hand.After measuring particle diameter in the time of 3 months; With embodiment 1-10 mix the suspensoid that forms respectively with embodiment 11,12, the suspensoid of control Example 1-1 to 8-2 is added a cover at 40 ℃ ± 2 ℃; Preserve under the situation of relative humidity 45% ± 5% after 24 hours, with descending concussion to carry out the particle diameter test after 10 seconds on hand.
Experimental result is following:
| Control Example 6-1 | 4.1±1.1 | 7.5±2.8 | 18.8±3.9 | 19.3±3.8 |
| Control Example 6-2 | 4.5±1.0 | 8.1±2.9 | 19.4±3.7 | 23.1±3.9 |
| Control Example 7-1 | 4.8±1.2 | 9.3±2.9 | 24.4±4.2 | 24.2±4.0 |
| Control Example 7-2 | 4.4±1.1 | 7.5±2.9 | 20.7±3.9 | 26.8±4.1 |
| Control Example 8-1 | 4.3±1.1 | 9.2±3.5 | 23.0±3.9 | 24.6±3.5 |
| Control Example 8-2 | 4.5±1.0 | 8.7±3.0 | 22.8±3.7 | 22.9±3.6 |
Show through above-mentioned experiment; According to the technology among the present invention medicine is separated with the water that contains adjuvant,, mix again during use through storing for a long time; Less to grain diameter influence; After storing 24 hours under the pyritous condition, the D90 particle diameter remains on below the 10 μ m basically, and the drug microparticles profile is that sphere or type spherical ability than the maintenance particle diameter that does not have definite form are better simultaneously.And if with medicine and through forming suspensoid through long-time storage with the water that contains adjuvant, the ability of maintenance particle diameter is relatively poor, particle diameter obviously improves.
Embodiment 16 in-vitro percutaneous permeability tests
After getting 3 monthly age healthy rats and rat anesthesia execution in 10 day age; Eliminate belly wool with shears; Take off undamaged skin, remove subcutaneous tissue, be individually fixed in the liberation port of Franz diffusion cell after cleaning; Add the pH7.4 phosphate buffer in the receiving chamber and make release medium, keep endodermis to contact closely with solution.Get the 0.1ml medicinal liquid and be coated on the skin, regulate water-bath and make outer jacket layer temperature constant in (37 ± 1) ℃, mixing speed is 100rpm, draws release medium 4ml respectively at 0,0.15,0.5,0.75,1,1.5,2 hour, adds equivalent PBS liquid simultaneously.Discharge liquid and confirm concentration C i, try to achieve drug per unit area accumulation transit dose Q:Q=CiV/A according to following formula with the method for Chinese Pharmacopoeia version in 2010
In the formula, Q is a drug per unit area accumulation transit dose, and Ci is the drug level in the release medium in the t time, and V is the receiving chamber volume, and A is the skin diffusion area.With Q and C the time is carried out linear regression respectively, try to achieve permeability (J/ μ g.h
-1)
The preparation of experiment medicine: with embodiment 1-12, control Example 1-1 to 8-2 be divided into embodiment 1-10 group, control Example 1-1 to 8-2 organizes; Embodiment 11-12 organizes 500 every group; All the other every group 40 units at 40 ℃ ± 2 ℃, carry out stability test under the situation of relative humidity 75% ± 5%; Store after 3 months, wherein each 20 capsules getting of embodiment 1-10 group carry out permeability test.
Before carrying out permeability test; Get 10 capsular medicines and in ampoule, mix, get 10 capsular medicines with water that 10 units that embodiment 11 obtains contain adjuvant respectively and mix in ampoule with the water that 10 units that embodiment 12 obtains contain adjuvant respectively, and with on hand down concussion be coated on immediately on the 3 monthly age healthy rat skins after 10 seconds; Control Example 1-1 to 8-2 group is before carrying out permeability test, with descending concussion to be coated on immediately on the 3 monthly age healthy rat skins after 10 seconds on hand.
Likewise, 10 day age rat skin carry out same test.
Experimental result is following:
Through above-mentioned experiment; Can find out that the bigger control Example infiltration rate of particle diameter is obviously lower; And the less embodiment infiltration rate of particle diameter is higher; Especially obviously improve for the thin rat infiltration rate in 10 day age of skin, can explain that suspensoid in this more adapts to give skin thin child.
Claims (10)
1. a Transdermal absorption is treated dermopathic pharmaceutical composition, is made up of jointly the water that contains one or more skin pharmaceutic adjuvants that is 0.1-10 μ m fluticasone propionate as the D90 particle diameter of packing separately that is insoluble in water, packs separately.
2. pharmaceutical composition as claimed in claim 1, the consumption that it is characterized in that said fluticasone propionate is 0.01%～0.2%.
3. the pharmaceutical composition described in claim 1 is characterized in that adjuvant in the water that contains one or more skin pharmaceutic adjuvants of said independent packing comprises one or more in pH regulator agent, osmotic pressure regulator, viscosity modifier, penetrating agent, surfactant or the stabilizing agent.
4. the dermal drug compositions described in claim 3 is characterized in that pH regulator agent in the said adjuvant is one or more in phosphoric acid and salt, boric acid and salt thereof, citric acid and salt thereof, acetic acid and salt thereof, tartaric acid and salt thereof, hydrochloric acid, sodium hydroxide, potassium hydroxide, sodium carbonate, potassium carbonate, sodium bicarbonate, potassium bicarbonate, the tromethane.
5. the dermal drug compositions described in claim 3 is characterized in that osmotic pressure regulator in the said adjuvant is one or more in glycerol, propylene glycol, sodium chloride, potassium chloride, Sorbitol, the mannitol.
6. the dermal drug compositions described in claim 3; It is characterized in that viscosity modifier in the said adjuvant is one or more in sodium carboxymethyl cellulose, hydroxyethyl-cellulose, hydroxypropyl emthylcellulose, hydroxypropyl cellulose, polyvinyl alcohol, carboxy vinyl polymer, the polyvinyl pyrrolidone, consumption is 0.1%～2%.
7. the dermal drug compositions described in claim 3 is characterized in that the optional non-ionic surface active agent of surfactant in the said adjuvant.
8. the dermal drug compositions described in claim 3 is characterized in that the stabilizing agent in the said adjuvant is a disodiumedetate.
9. the dermal drug compositions described in claim 3 is characterized in that penetrating agent in the said adjuvant is one or more in azone, sulfoxide and analog thereof, ethanol, aliphatic alcohol, pyrrolones, fatty acid, menthol, quintessence oil, the Borneolum Syntheticum.
10. like arbitrary described pharmaceutical composition in the claim 1 to 9, treat the application in human or animal's scytitis medicine in preparation.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2010105567782A CN102475708A (en) | 2010-11-23 | 2010-11-23 | Separate type water suspension medicine comprising fluticasone propionate and adjuvant-containing water and used for treating skin diseases |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2010105567782A CN102475708A (en) | 2010-11-23 | 2010-11-23 | Separate type water suspension medicine comprising fluticasone propionate and adjuvant-containing water and used for treating skin diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN102475708A true CN102475708A (en) | 2012-05-30 |
Family
ID=46088566
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2010105567782A Pending CN102475708A (en) | 2010-11-23 | 2010-11-23 | Separate type water suspension medicine comprising fluticasone propionate and adjuvant-containing water and used for treating skin diseases |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102475708A (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1652748A (en) * | 2002-04-17 | 2005-08-10 | 奇斯药制品公司 | Process for preparation of a sterile suspension of corticosteroid particles for the administration by inhalation |
| CN101798331A (en) * | 2008-12-25 | 2010-08-11 | 国家纳米技术与工程研究院 | Process for preparing fluticasone diproprionate superfine particles and product thereof |
-
2010
- 2010-11-23 CN CN2010105567782A patent/CN102475708A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1652748A (en) * | 2002-04-17 | 2005-08-10 | 奇斯药制品公司 | Process for preparation of a sterile suspension of corticosteroid particles for the administration by inhalation |
| CN101798331A (en) * | 2008-12-25 | 2010-08-11 | 国家纳米技术与工程研究院 | Process for preparing fluticasone diproprionate superfine particles and product thereof |
Non-Patent Citations (2)
| Title |
|---|
| 于淞: "《皮肤科临床外用药物》", 30 November 1975, article "激素类药", pages: 35-37 - 72 * |
| 侯绍蔚: "0.05%丙酸氟替卡松乳膏治疗皮炎湿疹临床疗效观察", 《长治医学院学报》, vol. 21, no. 3, 30 June 2007 (2007-06-30), pages 220 - 221 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20040147578A1 (en) | Use of lipoaminoacids as absorption promoters in a pharmaceutical composition | |
| EP2776014A2 (en) | Melatonin-based solutions and powders for their preparation | |
| CN102458557A (en) | Novel formulations of volatile anesthetics and methods of use for reducing inflammation | |
| CN102475681A (en) | Separation-type water suspension medicament for treating dermatopathy | |
| CN1706371B (en) | Efficient sword-like iris seed preparation and its preparation process | |
| CN102657602B (en) | 3,5-dyhydroxyl-4-isopropyl diphenylethene chitosan gel and preparation method thereof | |
| CN102481287A (en) | Pharmaceutical composition of temozolomide comprising vitamin c or vitamin c derivative and preparation method thereof | |
| CN104688721A (en) | Anti-rheumatoid arthritis drug gel containing paclitaxel liposome and preparation method of gel | |
| CN102525913A (en) | Separated water suspension medicine composed of hydrocortisone butyrate and water containing accessories and used for treating dermatosis | |
| CN102552283B (en) | Transdermal absorption drug for skin prepared from hydrocortisone butyrate containing adjuvant and water containing adjuvant | |
| CN100502850C (en) | Medicinal composition of total capsicine compounds and beta-cyclodextrin or derivative of beta-cyclodextrin | |
| CN107789320B (en) | Fulvestrant sustained-release injection and preparation process thereof | |
| CN102552287A (en) | Skin percutaneous absorption drug of adjuvant-containing mometasone furoate and adjuvant-containing water | |
| CN102552282A (en) | Transdermal absorption medicament used for skins and comprising adjuvant-containing methylprednisolone aceponate and adjuvant-containing water | |
| CN102475708A (en) | Separate type water suspension medicine comprising fluticasone propionate and adjuvant-containing water and used for treating skin diseases | |
| CN102526066A (en) | Separate type water suspension medicament of fluticasone propionate containing auxiliary materials for treating skin disease | |
| CN102552286A (en) | Separation type aqueous suspension medicament used for treating dermatopathy and formed by mometasone furoate and adjuvant-containing water | |
| CN102525912A (en) | Separated water suspension medicament consisting of methylprednisolone aceponate and water containing auxiliary materials for treating skin disease | |
| CN104337757A (en) | Ketoprofen transdermal nanocrystalline gel and preparation method thereof | |
| CN102475888A (en) | Transdermally absorbed medicine comprising adjuvant-containing pharmaceutical microparticle and adjuvant-containing water for skin use | |
| CN102657659A (en) | Transdermally-absorbed medicament used for skin and consisting of adjuvant-containing fluticasone propionate and adjuvant-containing water | |
| CN110339169A (en) | Coat nano vesicle preparations and its application of vitamin D and vitamin K | |
| CN102552130A (en) | Adjuvant-containing methylprednisolone aceponate separation type water suspension agent drug for treating skin diseases | |
| CN102552131A (en) | Accessory-containing hydrocortisone butyrate divided water suspension medicament for treating dermatopathy | |
| CN101623286A (en) | Transdermal administration composite containing cucurbitacin-type active ingredient |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20120530 |